Cargando…
Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma
BACKGROUND: CD133 is considered a marker for cancer stem cells (CSCs) in several types of tumours, including hepatocellular carcinoma (HCC). Chimeric antigen receptor-specific T (CAR-T) cells targeting CD133-positive CSCs have emerged as a tool for the clinical treatment of HCC, but immunogenicity,...
Autores principales: | Yang, Chaopin, You, Jinqi, Pan, Qiuzhong, Tang, Yan, Cai, Liming, Huang, Yue, Gu, Jiamei, Wang, Yizhi, Yang, Xinyi, Du, Yufei, Ouyang, Dijun, Chen, Hao, Zhong, Haoran, Li, Yongqiang, Yang, Jieying, Han, Yulong, Sun, Fengze, Chen, Yuanyuan, Wang, Qijing, Weng, Desheng, Liu, Zhongqiu, Xiang, Tong, Xia, Jianchuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464109/ https://www.ncbi.nlm.nih.gov/pubmed/37635247 http://dx.doi.org/10.1186/s12916-023-03016-0 |
Ejemplares similares
-
SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway
por: Yang, Jieying, et al.
Publicado: (2022) -
Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma
por: Yang, Jieying, et al.
Publicado: (2023) -
Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin
por: Sun, Fengze, et al.
Publicado: (2021) -
Evaluation of METase-pemetrexed-loaded PEG–PLGA nanoparticles modified with anti-CD133–scFV for treatment of gastric carcinoma
por: Xin, Lin, et al.
Publicado: (2018) -
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
por: Kang, Chung Hyo, et al.
Publicado: (2020)